{
    "clinical_study": {
        "@rank": "156555", 
        "arm_group": {
            "arm_group_label": "Lu AE58054 30 mg + itraconazole 200 mg", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To examine the effect of the strong CYP3A4/5 inhibitor itraconazole (200 mg QD) on the\n      multipledose exposure of Lu AE58054 (30 mg QD) in healthy subjects (CYP2D6 extensive\n      metabolisers)."
        }, 
        "brief_title": "Effect of Multiple Doses of Itraconazole on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects", 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects are eligible for inclusion into the study if they meet each of the following\n        criteria:\n\n          -  Men and women, aged 18 - 45 years.\n\n          -  Body weight at least 50 kg and Body Mass index 19 - 28 kg/m2.\n\n          -  Good general health ascertained by a detailed medical history, laboratory tests and\n             physical examination.\n\n          -  Non-childbearing potential or use of contraception (both sexes).\n\n          -  Women must not be pregnant or lactating.\n\n          -  Known CYP2D6 genotype (Extensive metaboliser (n=15) and poor metaboliser (n =5)) .\n\n        Other Inclusion and Exclusion Criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02122692", 
            "org_study_id": "15820A", 
            "secondary_id": "2013-003597-27"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lu AE58054 30 mg + itraconazole 200 mg", 
                "description": "Lu AE58054 encapsulated film-coated tablets, once daily, Day 1-5, orally", 
                "intervention_name": "Lu AE58054 30 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lu AE58054 30 mg + itraconazole 200 mg", 
                "description": "Lu AE58054 encapsulated film-coated tablets, once daily, Day 6-11, orally + itraconazole capsules, once daily, Day 6-11, orally", 
                "intervention_name": "Lu AE58054 30 mg + itraconazole 200 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lu AE58054 30 mg + itraconazole 200 mg", 
                "description": "Itraconazole capsules, once daily, Day 12-13, orally", 
                "intervention_name": "Itraconazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Itraconazole", 
                "Hydroxyitraconazole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rennes", 
                    "country": "France", 
                    "zip": "35042"
                }, 
                "name": "FR801"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Interventional, Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of Itraconazole (Inhibitor of CYP3A4/5) on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects", 
        "overall_contact": {
            "email": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S"
        }, 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the Lu AE58054 plasma concentration-time curve from time zero to 24 hours post-dose (AUC0-24)", 
                "safety_issue": "No", 
                "time_frame": "Day 5 and Day 11"
            }, 
            {
                "measure": "Maximum observed concentration (Cmax) of Lu AE58054", 
                "safety_issue": "No", 
                "time_frame": "Day 5 and Day 11"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02122692"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Plasma pharmacokinetics for Lu AE58054: AUC0-24, Cmax, time at which maximum observed plasma concentration occurred (tmax), apparent oral clearance (CL/F), half life (t\u00bd) and apparent volume of distribution Vz/F", 
                "safety_issue": "No", 
                "time_frame": "Day 5 and Day 11"
            }, 
            {
                "measure": "Plasma pharmacokinetics for relevant metabolites: AUC0-24, Cmax, tmax, t\u00bd and metabolic ratio (MR)", 
                "safety_issue": "No", 
                "time_frame": "Day 5 and Day 11"
            }, 
            {
                "measure": "Plasma pharmacokinetic parameters for itraconazole: CTrough", 
                "safety_issue": "No", 
                "time_frame": "Day 6 to Day 13"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 18, including a safety follow-up"
            }, 
            {
                "measure": "Columbia Suicide Severity Rating Scale (C-SSRS) categorization based on Columbia Classification Algorithm of Suicide Assessment (C-CASA) definitions", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 18, including a safety follow-up"
            }
        ], 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}